Anti-Fibrotic Effects Of Nintedanib (bibf 1120) In Primary Human Lung Fibroblasts Derived From Patients With Idiopathic Pulmonary Fibrosis And From Non-Fibrotic Controls

被引：0
|
作者：
Hostettler, K. E. [1 ]
Papakonstantinou, E. [2 ]
Klagas, J. [2 ]
Karakiulakis, G. [2 ]
Zhong, J. [1 ]
Tamm, M. [1 ]
Lardinois, D. [1 ]
Roth, M. [1 ]
机构：
[1] Univ Basel Hosp, Basel, Switzerland
[2] Univ Thessaloniki, Thessaloniki, Greece
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3374
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Nintedanib: A Potent Inhibitor of Invadosome Formation by Lung Fibroblasts Derived from Patients with Idiopathic Pulmonary Fibrosis
    Lebel, M.
    Cliche, D.
    Charbonneau, M.
    Bilodeau, G.
    Cantin, A. M.
    Dubois, C. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [32] Anti-Fibrotic Effects Of Inhaled Interferon-Gamma Detected By Gene Expression In Patients With Idiopathic Pulmonary Fibrosis
    Condos, R.
    Hasaneen, N. A.
    Foda, H. D.
    Smaldone, G. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [33] Effects of Anti-Fibrotic Drugs on Transcriptome of Peripheral Blood Mononuclear Cells in Idiopathic Pulmonary Fibrosis
    Ishii, Daisuke
    Kawasaki, Takeshi
    Sato, Hironori
    Tatsumi, Koichiro
    Imamoto, Takuro
    Yoshioka, Keiichiro
    Abe, Mitsuhiro
    Hasegawa, Yoshinori
    Ohara, Osamu
    Suzuki, Takuji
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [34] Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
    Yoshikawa, Takumi
    Otsuka, Mitsuo
    Chiba, Hirofumi
    Ikeda, Kimiyuki
    Mori, Yuki
    Umeda, Yasuaki
    Nishikiori, Hirotaka
    Kuronuma, Koji
    Takahashi, Hiroki
    BMC PULMONARY MEDICINE, 2020, 20 (01)
  • [35] Anti-Fibrotic Therapy for Idiopathic Pulmonary Fibrosis Is Associated with Decreased Mortality Among Hospitalized Patients
    Kelly, B.
    Thao, V.
    Dempsey, T. M.
    Sangaralingham, L.
    Payne, S.
    Limper, A. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [36] Anti-fibrotic Effects of Pirfenidone in Gut-derived Fibroblasts from Patients with Active Crohn's Disease
    Kadir, S. -I.
    Kragstrup, T. W.
    Dige, A.
    Jensen, S.
    Dahlerup, J. F.
    Kelsen, J.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S78 - S78
  • [37] Characteristics Of Patients With Idiopathic Pulmonary Fibrosis (ipf) Receiving Approved Anti-Fibrotic Therapies In The Us
    Gamerman, V.
    Salisbury, M.
    Culver, D.
    Leonard, T.
    Neely, M. L.
    Yow, E.
    Conoscenti, C. S.
    Palmer, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [38] Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model
    Li, Xiaohe
    Lv, Ziwei
    Huang, Kai
    Gan, Wenhua
    Gao, Shaoyan
    Yang, Bo
    Helian, Kaiyue
    Zhou, Honggang
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [39] Anastomotic Outcomes in Idiopathic Pulmonary Fibrosis Patients Receiving Anti-Fibrotic Therapy: Experience of the Australian Lung Transplant Collaborative
    Mackintosh, J.
    Munsif, M.
    Thomson, C.
    Musk, M.
    Snell, G.
    Glanville, A.
    Chambers, D.
    Hopkins, P.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S89 - S90
  • [40] Evidence of increased pluripotent cells in adult human lung tissue derived from fibrotic lungs compared to non-fibrotic control lungs
    Hostettler, Katrin
    Gazdhar, Amiq
    Geiser, Thomas
    Tamm, Michael
    Lardinois, Didier
    Roth, Michael
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
12345